Project Consultancy, Reports & Profiles

Medicinal plants sit at the crossing point of India's oldest healing traditions and one of its fastest-growing manufacturing opportunities. Global consumers are moving away from synthetic drugs toward plant-based alternatives, and India's mix of biodiversity, low-cost farmland, and centuries of Ayurveda experience gives entrepreneurs a genuine head start. That combination is why medicinal plants manufacturing now ranks among the more resilient business ideas for MSMEs and first-generation founders. The business scales in either direction — from a two-acre cultivation plot to a full extraction-and-export unit — and demand keeps climbing on both ends of that chain.

Why Medicinal Plants Manufacturing Is a Smart Business Idea Right Now

The shift from synthetic to herbal medicine is not a passing trend. Ayurveda and traditional Chinese medicine have built decades of consumer trust, and modern wellness brands now borrow directly from that credibility. For a manufacturer, this means the raw-material story — where a herb was grown, how it was processed — sells the finished product almost as much as the formulation itself does.

The economics work in India's favour too. Growing medicinal herbs is often more profitable than growing cereals or standard horticulture crops on comparable land. A farmer cultivating atis in the higher reaches of Uttarakhand or Himachal Pradesh, for instance, can earn roughly ₹2.5–3 lakh per acre — several times what a similar cereal crop would return (industry estimates). That gap is what keeps pulling new cultivators, and eventually new processors, into the sector every year.

That gap between India's raw potential and its actual global share is the real opportunity. Existing players cannot process the full volume of raw material India already grows, so a large share of the crop still leaves the country unprocessed, or gets exported as low-value raw herb instead of a higher-margin extract or finished formulation.

Market Demand & Statistics for Medicinal Plants in India

Demand for medicinal plants runs through four broad buyer groups: Ayurvedic and herbal pharmaceutical companies, nutraceutical and dietary-supplement makers, cosmetics and personal-care brands, and direct exporters of dried herb or extract. Each segment is growing at a different pace, but none of them is shrinking.

The India herbal medicine market was valued at roughly USD 6.3 billion in 2024 and is projected to touch close to USD 7.3 billion in 2025, on its way to nearly USD 30 billion by 2035 — a compound annual growth rate of about 15% (Market Research Future estimate). Dietary supplements currently form the largest slice of that market, while herbal cosmetics is the fastest-growing segment.

Zoom out to the wider Ayush and alternative-medicine category, and the number gets bigger still: an estimated USD 26.5 billion in 2026, moving toward USD 36.6 billion by 2031 (Mordor Intelligence estimate). Within that, the medicinal plant-extract segment specifically — the part most relevant to a processing or extraction business — was valued near USD 884 million in 2024 and is expected to more than double, crossing USD 2 billion by 2035 (Market Research Future estimate).

India's underlying resource base backs up these numbers. The country holds an estimated 17,000–18,000 flowering plant species, of which 6,000–7,000 are documented for therapeutic use across Ayurveda, Siddha, Unani, Sowa-Rigpa, and folk medicine systems. Roughly 960 species are actively traded, and 178 of those already see annual consumption above 100 metric tonnes (NMPB data) — a useful pointer to which species already have an established, de-risked market.

Government Policies, Incentives & Facilities for Medicinal Plants Projects

The Ministry of AYUSH runs the primary support structure for this sector through the National Medicinal Plants Board (NMPB). Its Central Sector Scheme for Conservation, Development and Sustainable Management of Medicinal Plants offers cultivation subsidies of 30%, 50%, or 75% of cost, depending on the species and applicant category, for 140 prioritised medicinal plants grown on farmers' land (NMPB scheme guidelines). The same scheme funds nurseries, quality planting material, post-harvest infrastructure, and market linkages.

A parallel channel, the medicinal plants component of the National AYUSH Mission, has already supported cultivation across more than 56,000 hectares nationwide between FY2015-16 and FY2020-21 (Ministry of AYUSH data), and continues to fund new projects through 37 State Medicinal Plants Boards and six Regional Cum Facilitation Centres.

State-level support varies but is real. Madhya Pradesh, which already accounts for close to 44% of national medicinal-plant production by volume (industry estimates), backs cultivation clusters through its state industrial and agro-processing policies. Uttarakhand, given its hill agro-climate, runs a dedicated state push on herbal research and aromatic-plant processing. Jammu & Kashmir's Medicinal Plants Board recently secured NMPB approval for 100 school herbal gardens, a small but telling sign of how actively the state-level machinery keeps expanding awareness and future supply at the grassroots.

On the MSME finance side, standard national schemes apply on top of this sector-specific support: CGTMSE-backed collateral-free loans, technology-upgradation support under CLCSS-linked schemes, and Startup India registration benefits for newer ventures. Exporters can additionally draw on the RoDTEP export-incentive scheme and Market Access Initiative funding for trade fairs and buyer-seller meets, administered through SHEFEXIL for raw herb exports and PHARMEXCIL for herbal pharmaceutical exports.

Market Growth & Industry Growth Outlook

Growth in this sector is accelerating, not just continuing. India's medicinal and aromatic plant segment grew at roughly 8.7% CAGR between 2020 and 2024; that rate is projected to climb to about 10.1% for 2025-2035 (Future Market Insights estimate) — faster than the global average of 8.1% for the same period.

Three forces are driving that acceleration. First, nutraceuticals and plant-derived dietary supplements are pulling demand beyond traditional Ayurveda-only products into a broader wellness category. Second, essential-oil output for perfumery and cosmetics is expected to more than double by 2032 as personal-care brands localise sourcing (industry estimate). Third, institutional credibility keeps rising: the World Health Organization's Global Centre for Traditional Medicine, based in Jamnagar, gives Indian-sourced herbal products a scientific stamp that export buyers increasingly look for.

Distribution is changing just as fast as production. E-commerce and direct-to-consumer channels already account for more than a quarter of Ayush-sector sales, and that channel is growing at close to 16% CAGR (Mordor Intelligence estimate) — well ahead of traditional pharmacy retail.

India's Herbal & Medicinal Plants Market (2022–2035)

Figures for 2022, 2023, 2030, and 2035 are derived by applying the CAGR trend reported by Market Research Future — roughly 8.7% historically, accelerating to about 15.2% through 2035 — to the confirmed 2024 and 2025 base figures. Treat all forward-looking numbers as industry estimates, not confirmed results.

Market Forecast to 2035

By 2035, India's herbal and medicinal plants market could realistically triple from where it stands today, crossing USD 30 billion if the current ~15% compound growth rate holds (assumption based on Market Research Future's 2025-2035 CAGR projection). That is not a guarantee — CAGR-based forecasts assume steady policy support and stable export demand — but the direction is consistent across every major research house covering the sector.

Two structural shifts support that trajectory. Contract-farming tie-ups between processors and cultivators are expected to expand to around 200,000 hectares by 2030 (Future Market Insights estimate), which would give manufacturers far more predictable raw-material supply than today's largely wild-harvested model. At the same time, global buyers are shifting spend from finished Ayurveda products toward plant-derived nutraceuticals and cosmeceutical ingredients — a segment where India currently under-participates relative to the size of its raw-material base.

For a new entrant, the practical takeaway is timing. Capacity built and certified over the next two to three years would be positioned to catch the steeper part of this growth curve, rather than entering once margins have already compressed under heavier competition.

Import–Export Opportunity for Medicinal Plants Manufacturers

India's Ayush and herbal exports have grown every year for the past four years running: USD 612 million in FY2021-22, USD 628 million in FY2022-23, USD 651 million in FY2023-24, and USD 689 million in FY2024-25 (Ministry of Commerce trade data) — a compound rise of nearly 13% over that stretch. Export volume grew even faster than value in the latest year, up 21.5% to about 1.29 lakh tonnes, which suggests exporters are currently selling more raw and lightly processed material rather than higher-value finished extracts.

That concentration is itself the opportunity. A large share of export earnings still comes from raw or minimally processed plant material rather than standardised extracts, essential oils, or finished nutraceutical ingredients — categories that typically carry two to four times the margin of raw herb. Entrepreneurs who invest in extraction and standardisation capacity, rather than raw cultivation alone, are positioned to capture that margin gap directly.

On the import side, India still brings in certain standardised phytopharmaceutical extracts and specialty botanicals that it grows domestically but does not yet process to export-grade purity at scale — a gap that points to clear import-substitution potential for a domestic extraction unit built around the right quality certifications.

Major Indian Players in the Medicinal Plants & Herbal Sector

Future Growth Potential and Reasons to Consider This Sector

Several tailwinds make this a reasonable sector to enter now rather than wait. Global institutional recognition is rising — WHO's Global Centre for Traditional Medicine in Jamnagar gives Indian herbal science a level of credibility it did not have a decade ago. Domestic demand is also broadening beyond classical Ayurveda into nutraceuticals, functional foods, and herbal cosmetics, which multiplies the number of buyers a single processing unit can sell into.

The sector also suits India's MSME structure particularly well. Cultivation is labour-intensive and works on relatively small landholdings, which matches how most Indian farmers actually operate. Processing can start small — a dryer, a grinder, a basic extraction line — and scale up as buyer contracts grow, rather than demanding large upfront capital the way some manufacturing sectors do.

Government support reduces some of that early risk directly. Between NMPB cultivation subsidies, state herbal-board infrastructure grants, and MSME credit-guarantee schemes, a well-prepared applicant can realistically cover a meaningful share of project cost through non-equity sources before approaching a bank for the balance.

Investment & Cost Estimates for Medicinal Plants Projects

These are illustrative, industry-estimate ranges meant for early planning only. Actual project cost depends on the specific plant species, location, machinery vendor, and land cost. A detailed, site-specific project report is recommended before finalising any investment decision.

FAQs for First-Time Medicinal Plants Entrepreneurs

How much capital does a small medicinal plants processing unit need?

A basic drying-and-powdering unit can start at roughly ₹20–35 lakh in total project cost, while an extraction-grade facility typically needs ₹2–3 crore (industry estimate). The right starting scale depends on whether you plan to sell raw processed herb or move into extracts.

What government subsidies apply to medicinal plant cultivation?

The NMPB's Central Sector Scheme covers 30–75% of cultivation cost for 140 prioritised species, on top of separate support for nurseries, post-harvest infrastructure, and marketing through the National AYUSH Mission.

Do I need special certification to export herbal raw material?

Yes. Exporters typically need a phytosanitary certificate, FSSAI licensing for food-grade herbs, pesticide-residue and heavy-metal testing, and registration with the relevant export promotion council — SHEFEXIL or PHARMEXCIL, depending on the product.

Which medicinal plants tend to give the fastest returns for a new grower?

Species already in heavy trade — amla, ashwagandha, aloe vera, isabgol, and giloy — tend to have the most established buyer networks and price discovery, which lowers the risk of an unsold harvest compared with less-traded species.

Can cultivation and processing be combined in one project?

Yes, and it is often the stronger business model. Integrating a small drying or extraction unit with your own cultivation removes dependence on third-party raw material and captures more of the margin within a single project.

What licenses does a medicinal plants manufacturing unit need in India?

At minimum, expect to register for MSME/Udyam and GST, secure an FSSAI license if the output touches food or supplements, obtain state pollution control clearance for processing units, and get AYUSH licensing if you manufacture classical formulations rather than just raw extracts.

The Bottom Line

Medicinal plants manufacturing is not a speculative bet on a passing trend — it is a sector with a documented four-year export growth streak, active government subsidy support, and a domestic resource base most competing countries simply do not have. What India lacks is enough processing capacity close to where the plants are actually grown.

That gap is the entry point. Whether you start with a contract-cultivation model, a small extraction unit, or an export-trading operation built around already-traded species, the fundamentals support steady rather than explosive growth — which, for a first-generation entrepreneur, is usually the safer kind to build a business on. A detailed, site-specific feasibility study remains the right next step before committing capital, since the right species, capacity, and location can shift the numbers in this article significantly.